Swissmedic is adapting its review practice for new applications for medicinal products containing the known active substance paclitaxel as paclitaxel albumin to the new EMA guideline
So that Swissmedic can efficiently process its business-relevant documents in the long term, it is launching an invitation for tenders to supply a records management system
Shortening of time limits for applications for new authorisation of medicinal products with known active substances without innovation under Art. 13 TPA
With effect from 27.08.2025, the official publication website for product information texts approved by Swissmedic for veterinary medicinal products is changing
With the new UDI Devices module, registering medical devices, including in vitro diagnostic medical devices, in the swissdamed database is now available
